Trial Profile
A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 09 Feb 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 03 Aug 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2023.
- 30 Jan 2023 Planned End Date changed from 31 Dec 2022 to 30 Jun 2023.